WGS GeneDx Holdings Corp.
Services-Health Services · Nasdaq · SEC CIK 1818331 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.6%
TTM net income YoY-5,431.2%
TTM EPS YoY-3,518.2%
Revenue 3-yr CAGR30.7%
Net income 3-yr CAGR—
Margins
Gross margin68.7%
Operating margin-21.6%
Net margin-24.1%
FCF margin-22.0%
EBITDA margin-19.0%
Returns
ROE-41.4%
ROA-21.8%
ROIC (approx.)-29.0%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets53.5%
Debt / equity0.60x
Current ratio4.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $427.54M | $305.45M |
| Cost of revenue | $129.37M | $111.05M |
| Gross profit | $298.17M | $194.40M |
| R&D expense | $72.03M | $45.72M |
| SG&A expense | $150.82M | $104.52M |
| Operating income | -$13.08M | -$23.21M |
| Pretax income | -$21.14M | -$52.63M |
| Income tax | -$116,000 | -$343,000 |
| Net income | -$21.02M | -$52.29M |
| EBITDA | -$3.48M | -$15.31M |
| EPS (basic) | -0.73 | -1.94 |
| EPS (diluted) | -0.73 | -1.94 |
| Weighted avg. shares (diluted) | 28.64M | 26.89M |
| Balance sheet | ||
| Cash & equivalents | $105.00M | $86.20M |
| Short-term investments | $66.28M | $55.97M |
| Receivables | $74.37M | $37.63M |
| Inventory | $13.95M | $10.65M |
| Current assets | $268.29M | $197.97M |
| PP&E, net | $45.69M | $32.89M |
| Goodwill | $13.52M | $0 |
| Intangibles | $168.48M | $158.60M |
| Total assets | $523.71M | $419.38M |
| Current liabilities | $108.91M | $54.82M |
| Short-term debt | $4.54M | $1.21M |
| Long-term debt | $48.18M | $51.91M |
| Total debt | $52.72M | $53.12M |
| Total liabilities | $215.53M | $174.13M |
| Shareholders' equity | $308.18M | $245.25M |
| Net debt | -$52.28M | -$33.08M |
| Shares outstanding | 29.25M | 28.02M |
| Cash flow statement | ||
| Operating cash flow | $33.28M | -$28.50M |
| Capital expenditure | $19.02M | $5.49M |
| Free cash flow | $14.26M | -$33.99M |
| Investing cash flow | -$61.52M | -$30.13M |
| Financing cash flow | $48.02M | $44.16M |
| Depreciation & amortization | $9.60M | $7.90M |
| Stock-based compensation | $32.16M | $9.14M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.